Abstract
A 53-year-old woman was treated, after trastuzumab progression of HER2-positive metastatic disease, with capecitabine plus lapatinib and subsequently with lapatinib alone. To date, she has had persistent remission of disease since 2009.
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology*
-
Capecitabine
-
Carcinoma, Ductal, Breast / chemistry
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / secondary
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Disease-Free Survival
-
Drug Administration Schedule
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Lapatinib
-
Letrozole
-
Lymphatic Metastasis
-
Middle Aged
-
Molecular Targeted Therapy / methods
-
Nitriles / administration & dosage
-
Paclitaxel / administration & dosage
-
Protein Kinase Inhibitors / administration & dosage
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Quality of Life
-
Quinazolines / administration & dosage
-
Receptor, ErbB-2 / analysis
-
Receptor, ErbB-2 / drug effects*
-
Trastuzumab
-
Treatment Outcome
-
Triazoles / administration & dosage
Substances
-
Antibodies, Monoclonal, Humanized
-
Nitriles
-
Protein Kinase Inhibitors
-
Quinazolines
-
Triazoles
-
Lapatinib
-
Deoxycytidine
-
Capecitabine
-
Letrozole
-
ERBB2 protein, human
-
Protein-Tyrosine Kinases
-
Receptor, ErbB-2
-
Trastuzumab
-
Paclitaxel
-
Fluorouracil